Work

Effects of the retinoic receptor agonists on proliferation of myelocytic leukemia cells

Year: 2018

Type: article

Abstract: All-trans retinoic acid (ATRA) is used to treat some of acute myelocytic leukemia (AML) such as acute promyelocytic leukemia (APL). Since ATRA shows biological activities binding to its receptor retinoic acid receptor (RAR), we compared anti-proliferative activity against AML cell line HL-60 cells between ATRA as pan-RAR agonist and tamibarotene and Am580 as RAR alpha agonist. We investigated effects of tamibarotene and Am580 synthesized as retinoic acid receptor agonists compared with ATRA. HL-60 cells were incubated with ATRA, tamibarotene and Am580 for several days. Cell number was counted and total RNA was extracted from the cells after the incubation. Quantitative RT-PCR was performed to quantify the mRNA levels of cyclin A2, cyclinD1, c-myc, CD11b, and glyceraldehyde-3-phospahte dehydrogenase as internal control.

Source: Proceedings for Annual Meeting of The Japanese Pharmacological Society

DOI: 10.1254/jpssuppl.wcp2018.0_po4-6-47

Authors: Takeaki Nitto, Yasuko Ohnuki, Tomoko Matsuda, Mizuki Saegusa, Rina Matsuda, Asako Tanaka, Kohei Sawaki

Institution: Yokohama University of Pharmacy

Language: English

Topic: Retinoids in leukemia and cellular processes

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W3084044657

FWCI:

Cites:

Cited by:

Related to: 10